Johnson & Johnson (NYSE:JNJ) is one The best stocks that will make you rich in 10 years.
Reuters reported on March 5 that two Johnson & Johnson (NYSE: JNJ ) units have agreed to settle claims by health plans and others that they overcharged for the pulmonary hypertension drug Tracleer. The plaintiffs included the State Employees Health Union and other agencies that paid for or paid for the use of Tracleer by their members, and their lawsuit alleged that competition for generic prescriptions of the drug was stifled by drugmakers. The lawsuit alleges that the drugmakers blocked a competitor’s access to Troclir samples, which they said “effectively prevented the competitor from bringing a competing generic product to market for a period of time.”
A preliminary settlement with Actelion Pharmaceuticals and Johnson Research & Development was filed in federal court in Maryland, with the proposal requiring a judge’s approval. Actelion made billions of dollars from the sale of Tracleer, an oral treatment for pulmonary arterial hypertension, and was acquired by Johnson & Johnson (NYSE:JNJ) in 2017, Reuters added. Johnson & Johnson (NYSE:JNJ) did not immediately respond to a request from Reuters.
Johnson & Johnson (NYSE: JNJ ) develops, manufactures and sells products in the healthcare field. The company operates through two segments: Innovative Medicines and MedTech. The Innovative Medicines segment focuses on various therapeutic areas, including oncology, infectious diseases, immunology, cardiovascular and metabolic diseases, and others. The MedTech segment includes a wide range of medical devices and products used in the cardiac interventional, orthopedic, interventional solutions, surgical, and vision fields.
While we recognize JNJ’s potential as an investment, we believe some AI stocks offer higher potential and lower risk. If you’re looking for the most undervalued AI stocks that stand to benefit significantly from Trump-era tariffs and the offshore trend, check out our free report Best short-term AI stocks.
Read more: The best and worst Dow stocks for the next 12 months and 10 unstoppable stocks that can double your money.
Disclosure: None. Follow the inside port on Google News.
